We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Clavis Pharma Receives Government Grant to Develop hENT1 Biomarker Assay for Targeted Therapy of AML Patients

News   Jun 01, 2011

 
Clavis Pharma Receives Government Grant to Develop hENT1 Biomarker Assay for Targeted Therapy of AML Patients
 
 
Advertisement
 

RELATED ARTICLES

AI Algorithm Detects Osteoarthritis Years Before Symptoms Develop

News

Researchers have created a machine-learning algorithm that can detect subtle signs of osteoarthritis, often missed by trained radiologists, on an MRI scan taken years before symptoms even begin.

READ MORE

Routine Blood Test Predicts Increased Mortality Risk in Patients With COVID-19

News

A standard test that assesses blood cells can identify which patients who are admitted to the hospital with COVID-19 face a high risk of becoming critically ill and dying.

READ MORE

Creavo Medical Technologies Appoints Martin Frost as Chairman

News

Creavo Medical Technologies Ltd (Creavo), the medical device company developing innovative diagnostics techniques, has announced that it has appointed Martin Frost as Chairman of the Board of Directors.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Proteomics & Metabolomics

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE